Germline testing for breast cancer should also include the PALB2 gene, considering the frequency of pathogenic defects in the general population and because PALB2 heterozygotes should be considered for the same therapeutic regimens and clinical trials as those for BRCA1 and BRCA2 carriers. This evidence concerns the gene BRCA2 and breast cancer.